Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218573

SCHEMBL23218573

SCHEMBL23218573

CC(C)(C)OC(=O)Cc1ccccc1OCc1cc2cc(COc3ccccc3)cc(I)c2o1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 11/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MTNR1A P48039 2/20 0.35
▸ MTNR1B P49286 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ F11 P03951 4/20 0.34
▸ KLKB1 P03952 3/20 0.34
▸ TPSB2 P20231 2/20 0.34
▸ PLG P00747 1/20 0.34
▸ PLAU P00749 1/20 0.34
▸ F7 P08709 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852443 1.00 CFD (0.37) CFDL3MBTL1MTNR1AMTNR1BNPC1
SCHEMBL23219011 0.90 TBXAS1 (0.38) CFDL3MBTL1MTNR1AMTNR1BF11
SCHEMBL29852925 0.90 TBXAS1 (0.38) CFDL3MBTL1MTNR1AMTNR1BF11
SCHEMBL29853229 0.90 MTNR1A (0.37) CFDL3MBTL1MTNR1AMTNR1BF11
SCHEMBL23218235 0.90 MTNR1A (0.37) CFDL3MBTL1MTNR1AMTNR1BF11
SCHEMBL23218513 0.88 MTNR1A (0.36) CFDL3MBTL1MTNR1AMTNR1BF11
SCHEMBL28772715 0.88 CFD (0.35) CFDMTNR1AMTNR1BF11KLKB1
SCHEMBL30009876 0.88 CFD (0.35) CFDMTNR1AMTNR1BF11KLKB1
SCHEMBL23219131 0.86 MTNR1A (0.37) CFDL3MBTL1MTNR1AMTNR1BNPC1
SCHEMBL23218702 0.84 MTNR1A (0.37) CFDL3MBTL1MTNR1AMTNR1BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885L3MBTL1 4262/4885MTNR1A 3930/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885L3MBTL1 4650/4885MTNR1A 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.